Insider Buying: AstraZeneca (LON:AZN) Insider Purchases £303,025 in Stock

AstraZeneca PLC (LON:AZN) insider Michel Demare acquired 2,500 shares of AstraZeneca stock in a transaction on Monday, September 14th. The shares were bought at an average price of £121.21 per share, for a total transaction of £303,025.

AstraZeneca Price Performance

AZN opened at £124.28 on Friday. The company has a 50-day moving average of £121.79 and a 200-day moving average of £134.47. The company has a market capitalization of £192.75 billion, a P/E ratio of 18.60, a PEG ratio of 0.86 and a beta of 0.20. AstraZeneca PLC has a 1-year low of £107.84 and a 1-year high of £157.32. The company has a debt-to-equity ratio of 64.10, a quick ratio of 0.59 and a current ratio of 0.89.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Berenberg Bank cut their price objective on AstraZeneca from £160 to £150 and set a “buy” rating on the stock in a research note on Tuesday. Jefferies Financial Group reiterated a “buy” rating and issued a £175 price target on shares of AstraZeneca in a report on Wednesday, September 9th. Citigroup upped their price target on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a £117 price objective on shares of AstraZeneca in a research note on Tuesday. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a £145 price objective on shares of AstraZeneca in a report on Tuesday, September 8th. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average target price of £150.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.